Plain-English translation of NCT06923761 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing GRWD5769, a new medication that works by changing how cancer tumors appear to your immune system, so your body can fight them more effectively. The study will test this medication both on its own and in combination with another cancer drug called cemiplimab. The goal is to see if this approach can help people with advanced cancers that have not responded to standard treatments.
Many patients with advanced cancer find that their immune system becomes exhausted and stops fighting the disease effectively. This medication is designed to 'wake up' the immune system by blocking a specific enzyme, allowing it to recognize and attack cancer cells again.
You likely qualify if…
You likely don't qualify if…
Participants will take the new medication by mouth daily while attending regular clinic visits for blood tests, scans, and check-ups to monitor how well the treatment is working and watch for side effects. Depending on which part of the study you join, you may take the medication alone or in combination with another cancer drug given through an IV. Some participants may also be asked to provide tumor tissue biopsies to help researchers understand how the medication is affecting the cancer.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Australia